BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 21839238)

  • 1. Calcineurin inhibitors in liver transplantation: to be or not to be.
    Castroagudín JF; Molina E; Varo E
    Transplant Proc; 2011; 43(6):2220-3. PubMed ID: 21839238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Everolimus in clinical practice in long-term liver transplantation: an observational study.
    Casanovas T; Argudo A; Peña-Cala MC
    Transplant Proc; 2011; 43(6):2216-9. PubMed ID: 21839237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term maintenance therapy with calcineurin inhibitors: an update.
    Campistol JM
    Transplant Proc; 2010 Nov; 42(9 Suppl):S21-4. PubMed ID: 21095445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current immunosuppressive approaches in liver transplantation.
    Iacob S; Cicinnati VR; Beckebaum S
    Panminerva Med; 2009 Dec; 51(4):215-25. PubMed ID: 20195232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion to everolimus in liver transplant patients with renal dysfunction.
    Pérez T; Segovia R; Castro L; Roblero JP; Estela R
    Transplant Proc; 2011; 43(6):2307-10. PubMed ID: 21839260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Operational tolerance: past lessons and future prospects.
    Levitsky J
    Liver Transpl; 2011 Mar; 17(3):222-32. PubMed ID: 21384504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcomes of calcineurin inhibitor withdrawal for post-liver transplant renal dysfunction.
    Mackay AJ; Angus PW; Gow PJ
    Transplant Proc; 2011 Dec; 43(10):3802-6. PubMed ID: 22172850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steroid and calcineurin inhibitor-sparing protocols in kidney transplantation.
    Helal I; Chan L
    Transplant Proc; 2011 Mar; 43(2):472-7. PubMed ID: 21440737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?
    Rostaing L; Kamar N
    J Nephrol; 2010; 23(2):133-42. PubMed ID: 20155724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical insights for cancer outcomes in renal transplant patients.
    Alberú J
    Transplant Proc; 2010 Nov; 42(9 Suppl):S36-40. PubMed ID: 21095450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New concepts to individualize calcineurin inhibitor therapy in renal allograft recipients.
    Sommerer C; Giese T; Meuer S; Zeier M
    Saudi J Kidney Dis Transpl; 2010 Nov; 21(6):1030-7. PubMed ID: 21060169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Causes of sirolimus discontinuation in 97 liver transplant recipients.
    Panaro F; Piardi T; Gheza F; Ellero B; Audet M; Cag M; Cinqualbre J; Wolf P
    Transplant Proc; 2011 May; 43(4):1128-31. PubMed ID: 21620069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. University of Modena experience in HIV-positive patients undergoing liver transplantation.
    Di Benedetto F; Tarantino G; De Ruvo N; Cautero N; Montalti R; Guerrini GP; Ballarin R; Spaggiari M; Smerieri N; Serra V; Rompianesi G; D'Amico G; Mimmo A; Iemmolo RM; Codeluppi M; Cocchi S; Guaraldi G; Gerunda GE
    Transplant Proc; 2011 May; 43(4):1114-8. PubMed ID: 21620066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver transplant: a primer.
    Movahedi Z; Holt CD; Saab S
    Exp Clin Transplant; 2010 Jun; 8(2):83-90. PubMed ID: 20565363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
    Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CNIs: immediate benefits but storing problems for the future?
    Kiuchi T
    Transplantation; 2008 Oct; 86(8):1026-7. PubMed ID: 18946338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term evaluation of cyclosporine and tacrolimus based immunosuppression in pediatric liver transplantation.
    Hasenbein W; Albani J; Englert C; Spehr A; Grabhorn E; Kemper MJ; Burdelski M; Ganschow R
    Pediatr Transplant; 2006 Dec; 10(8):938-42. PubMed ID: 17096762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conversion From Calcineurin to Mammalian Target of Rapamycin Inhibitors in Liver Transplantation: A Meta-Analysis of Randomized Controlled Trials.
    Glover TE; Watson CJ; Gibbs P; Bradley JA; Ntzani EE; Kosmoliaptsis V
    Transplantation; 2016 Mar; 100(3):621-9. PubMed ID: 26636736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcineurin inhibitor-free immunosuppression in kidney transplantation.
    Guerra G; Srinivas TR; Meier-Kriesche HU
    Transpl Int; 2007 Oct; 20(10):813-27. PubMed ID: 17645419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.